AARDHealthcare · BiotechnologyThe 12 Wall Street analysts covering Aardvark Therapeutics, Inc. hold a median 12-month price target of $6.5 — -8.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 1 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Aardvark Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (72): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Aardvark Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on AARD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −8.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | $6.00 |
| 15 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 15 May 2026 | B. Riley Securities | Maintains | Buy | $8.00 → $7.00 |
| 15 May 2026 | BTIG | Downgrade | Neutral | — |
| 15 May 2026 | BTIG | Downgrade | Neutral | — |
| 15 May 2026 | Morgan Stanley | Downgrade | Underweight | $7.00 → $3.00 |
| 15 May 2026 | Morgan Stanley | Downgrade | Underweight | — |
| 24 Mar 2026 | BTIG | Reiterates | Buy | — |
| 2 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 2 Mar 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 2 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 2 Mar 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 2 Mar 2026 | Stifel | Downgrade | Hold | — |
| 10 Feb 2026 | BTIG | Reiterates | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Dec 2025 | Oppenheimer | Initiates | Outperform | — |
| 12 Dec 2025 | William Blair | Initiates | Outperform | — |
| 14 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 7 Nov 2025 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 49% of US stocks
Cheaper than 66% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AARD appears on the weeks it earns a place.
On May 15, 2026, Aardvark Therapeutics shares fell 32% ($2.16) after the FDA placed a clinical hold on the company's Prader-Willi Syndrome drug candidate.
Why it matters — The FDA clinical hold on Aardvark's lead drug candidate represents a significant regulatory setback for the company's primary pipeline asset.
The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. have a median 12-month price target of $6.5, with estimates ranging from $3 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Aardvark Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Aardvark Therapeutics, Inc. 13 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Aardvark Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies -8.2% from the last close, and Ticker Nerd's factor model ranks Aardvark Therapeutics, Inc. 13 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aardvark Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $45 over the next 12 months.
Aardvark Therapeutics, Inc. returned -41.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel small-molecule therapies for metabolic and hunger-associated disorders.
The most recent item we track (PRNewsWire, 30 July 2026): "Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman". On May 15, 2026, Aardvark Therapeutics shares fell 32% ($2.16) after the FDA placed a clinical hold on the company's Prader-Willi Syndrome drug candidate.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel small-molecule therapies for metabolic and hunger-associated disorders. The company focuses on activating innate homeostatic pathways, particularly through selective targeting of Bitter Taste Receptors (TAS2Rs) in the gut to modulate appetite and related metabolic processes. Its lead product candidate, ARD-101, is an oral, gut-restricted small-molecule agonist of specific TAS2Rs being evaluated in advanced clinical trials for hyperphagia associated with Prader-Willi Syndrome and other hypothalamic causes of excessive hunger. Aardvark Therapeutics is also developing ARD-201, a small-molecule candidate in early-stage clinical development for obesity. Operating in the healthcare sector within the biotechnology industry, the company aims to address significant unmet medical needs in metabolic disease and weight management. Aardvark Therapeutics was incorporated in 2017 and is headquartered in San Diego, California, serving a global biopharmaceutical market through its research, development, and clinical collaboration activities.
CEO Dr. Tien-Li Lee M.D. · 40 employees · United States · https://aardvarktherapeutics.com